GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Interest Coverage

SILO Pharma (SILO Pharma) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. SILO Pharma's Operating Income for the three months ended in Mar. 2024 was $-0.88 Mil. SILO Pharma's Interest Expense for the three months ended in Mar. 2024 was $-0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for SILO Pharma's Interest Coverage or its related term are showing as below:


SILO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


SILO Pharma Interest Coverage Historical Data

The historical data trend for SILO Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SILO Pharma Interest Coverage Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SILO Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - No Debt -

Competitive Comparison of SILO Pharma's Interest Coverage

For the Biotechnology subindustry, SILO Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Interest Coverage falls into.



SILO Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SILO Pharma's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, SILO Pharma's Interest Expense was $-0.01 Mil. Its Operating Income was $-3.86 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

SILO Pharma did not have earnings to cover the interest expense.

SILO Pharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, SILO Pharma's Interest Expense was $-0.00 Mil. Its Operating Income was $-0.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

SILO Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


SILO Pharma  (NAS:SILO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


SILO Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma (SILO Pharma) Business Description

Traded in Other Exchanges
N/A
Address
560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797